-

SHAREHOLDER ALERT: Robbins LLP Investigates Ipsidy Inc. (AUID) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating the officers and directors of Ipsidy Inc. (NASDAQ: AUID) for breaches of fiduciary duties and violations of the securities laws. Ipsidy operates an Identity as a Service (IDaaS) platform that delivers a suite of secure, mobile, and biometric identity solutions worldwide.

If you would like more information about Ipsidy Inc.'s misconduct, click here.

Ipsidy Inc. (AUID) Is Accused of Misstating its Sources of Revenue

On December 16, 2021, White Diamond Research published a report alleging that Ipsidy "has nothing going for it" and its claims of being a "pure-play SaaS [software as a service] business" are misleading, as "[n]one of its revenues have been from its SaaS product … and 70% are from low tech, legacy businesses." The report claims the Company's revenues "aren't from its identity verification application" and that its "REAL businesses are selling plastic cards in South Africa and leasing bus ticket kiosks in Colombia." Regarding its financials, the report noted that in the quarter ended September 30, 2021, Ipsidy "had a loss of $5.2M and cash burn of $3.2M" and "will likely be out of cash" soon. Further, Ipsidy did not give any guidance in its Q321 earnings call. Finally, the Company's relationship with its newest customer, Hamilton Reserve Bank, is questionable and did not generate any new revenue in the quarter the relationship was announced.

If you own shares of Ipsidy Inc. (AUID), you have rights. Contact us for more information about your legal options.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Ipsidy Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom